When Statins Do Not Adequately Lower LDL-C: Novel Therapies to Improve Outcomes in Patients with HeFH and ASCVD
Faculty
James Underberg MD, FACP, MNLA
Clinical Assistant Professor of Medicine
Daniel Soffer, MD, FNLA, FACP
Clinical Associate Professor of Medicine Internal Medicine/Clinical Lipidology
Perelman School of Medicine
University of Pennsylvania Health System Philadelphia, PA
President-Elect National Lipid Association
Erin D. Michos, MD, MHS
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co-Editor in Chief of the American Journal of Preventive Cardiology
Program Overview
Target Audience
BROADCAST ONE
An Era Beyond Statins: Novel Lipid-Lowering Agents for Residual Cardiovascular Risk Reduction
BROADCAST TWO
The 2022 ACC Expert Consensus Decision Pathway: The Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD in Primary and Secondary Prevention
